Laekna's LAE120, a novel allosteric USP1 inhibitor, receives FDA IND approval for treating advanced solid tumors, demonstrating robust anti-tumor activity in various xenograft models.
Tango Therapeutics' lead candidate TNG462 has been granted Orphan Drug Designation by the FDA for pancreatic cancer treatment, providing seven years of market exclusivity upon approval.
Biopharma companies continue to announce layoffs in 2025, driven by strategic realignments, pipeline reprioritizations, and challenging financial conditions.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.